[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201100524A1 - Азаиндазолы в качестве антагонистов рецептора ccr1 - Google Patents

Азаиндазолы в качестве антагонистов рецептора ccr1

Info

Publication number
EA201100524A1
EA201100524A1 EA201100524A EA201100524A EA201100524A1 EA 201100524 A1 EA201100524 A1 EA 201100524A1 EA 201100524 A EA201100524 A EA 201100524A EA 201100524 A EA201100524 A EA 201100524A EA 201100524 A1 EA201100524 A1 EA 201100524A1
Authority
EA
Eurasian Patent Office
Prior art keywords
azaindazoles
antagonists
ccr1 receptor
compounds
application
Prior art date
Application number
EA201100524A
Other languages
English (en)
Inventor
Брайан Николас Кук
Даррин Дисалво
Даниел Роберт Фандрик
Кристиан Харкен
Даниел Кузмич
Томас Вай-Хо Ли
Пинрон Лю
Джон Лорд
Кань Мао
Йохен Ной
Брайан Кристофер Роденбуш
Хоссейн Разави
Джонатан Тимоти Ривз
Циньхуа Дж. Сон
Алан Дейвид Суинеймер
Чжулинь Тань
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201100524A1 publication Critical patent/EA201100524A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

В заявке описаны соединения формулы (I), применимые для лечения различных заболеваний и нарушений, которые опосредуются или поддерживаются активностью CCR1, включая аутоиммунные заболевания, такие как ревматоидный артрит и рассеянный склероз. В заявке также описаны методики получения и применения таких соединений.
EA201100524A 2008-09-26 2009-09-22 Азаиндазолы в качестве антагонистов рецептора ccr1 EA201100524A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10040108P 2008-09-26 2008-09-26
PCT/US2009/057778 WO2010036632A1 (en) 2008-09-26 2009-09-22 Azaindazole compounds as ccr1 receptor antagonists

Publications (1)

Publication Number Publication Date
EA201100524A1 true EA201100524A1 (ru) 2011-10-31

Family

ID=41349302

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100524A EA201100524A1 (ru) 2008-09-26 2009-09-22 Азаиндазолы в качестве антагонистов рецептора ccr1

Country Status (24)

Country Link
US (4) US7879873B2 (ru)
EP (1) EP2346868B1 (ru)
JP (1) JP5507567B2 (ru)
KR (1) KR20110060904A (ru)
CN (1) CN102227425A (ru)
AP (1) AP2739A (ru)
AR (1) AR073689A1 (ru)
AU (1) AU2009296839A1 (ru)
BR (1) BRPI0919844A2 (ru)
CA (1) CA2737472A1 (ru)
CL (1) CL2011000668A1 (ru)
CO (1) CO6351735A2 (ru)
EA (1) EA201100524A1 (ru)
EC (1) ECSP11010932A (ru)
IL (1) IL210857A0 (ru)
MA (1) MA32655B1 (ru)
MX (1) MX2011002951A (ru)
NZ (1) NZ591115A (ru)
PE (1) PE20110854A1 (ru)
TW (1) TW201018683A (ru)
UA (1) UA103634C2 (ru)
UY (1) UY32140A (ru)
WO (1) WO2010036632A1 (ru)
ZA (1) ZA201100625B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
RU2011142182A (ru) * 2009-03-19 2013-04-27 Медикал Рисерч Каунсил Текнолоджи Соединения
CN102666526A (zh) 2009-10-21 2012-09-12 贝林格尔.英格海姆国际有限公司 作为ccr1受体拮抗剂的吲唑和吡唑并吡啶化合物
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしての複素環化合物
US20110137042A1 (en) * 2009-12-08 2011-06-09 Boehringer Ingelheim International Gmbh Process for Synthesis of Intermediates Useful for Making Substituted Indazole and Azaindazole Compounds
EP2563787B1 (en) * 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
EP2388260A1 (de) * 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
WO2012031197A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Novel compounds and compositions for the inhibition of nampt
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN102775365A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
EP2771011A4 (en) * 2011-10-24 2015-04-15 Glaxosmithkline Ip No 2 Ltd CHEMICAL COMPOUNDS
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2820017B1 (en) * 2012-03-02 2016-12-21 Genentech, Inc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970306A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
FR3016879A1 (fr) * 2014-01-29 2015-07-31 Guillaume Laconde Procede de preparation de benzotriazole n-acyles
PL3119757T3 (pl) 2014-03-17 2018-09-28 Pfizer Inc. Inhibitory diacyloglicerolo acylotransferazy 2 do stosowania w leczeniu zaburzeń metabolicznych i związanych
MA46373A (fr) 2014-04-14 2019-08-07 Boehringer Ingelheim Int Composés utilisés comme modulateurs de ror gamma
JP6810988B2 (ja) 2015-10-23 2021-01-13 ヴィフォール (インターナショナル) アクチェンゲゼルシャフトVifor (International) AG 新規なフェロポーチン阻害剤
BR112018009579A2 (pt) 2015-11-13 2018-11-06 Basf Se composto da fórmula i, mistura, composição agroquímica, uso de composto e método de combate a fungos
US20180354920A1 (en) 2015-11-13 2018-12-13 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN109069514B (zh) 2016-03-07 2023-12-29 结核病药物开发全球联盟公司 抗菌化合物及其用途
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
CN112204010B (zh) * 2018-05-31 2024-03-19 C&C新药研究所 杂环衍生物及其用途
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
WO2021262878A1 (en) * 2020-06-24 2021-12-30 Oregon Health & Science University Novel molecule for modulation of innate immune responses controlled by sting protein

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2195129C (en) 1991-03-28 2002-09-10 Anabella Villalobos Substituted piperidine intermediates for producing heterocyclic-cyclic amine derivatives capable of inhibiting cholinesterase
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5616537A (en) 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
WO1995000509A1 (fr) 1993-06-25 1995-01-05 Kumiai Chemical Industry Co., Ltd. Derive d'indazolesulfonyluree, son utilisation et intermediaire pour sa production
AU699281B2 (en) 1994-12-06 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
CA2309175A1 (en) 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
WO2001000656A2 (en) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7058826B2 (en) 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
WO2008011131A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2003053941A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
EP1497278B1 (en) 2002-04-11 2010-05-26 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic amide derivatives as cytokine inhibitors
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
KR101255356B1 (ko) * 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ccr1 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
WO2005016929A1 (en) 2003-08-15 2005-02-24 Astrazeneca Ab Fused heterocylcles as inhibitors of glutamate racemase (muri)
WO2006091496A2 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
CN102617557A (zh) 2005-05-17 2012-08-01 萨可德生物科学公司 治疗眼病的组合物和方法
WO2007002293A2 (en) * 2005-06-22 2007-01-04 Chemocentryx, Inc. Azaindazole compounds and methods of use
AU2006287202B2 (en) 2005-09-01 2013-01-24 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
WO2007102883A2 (en) 2005-10-25 2007-09-13 Smithkline Beecham Corporation Chemical compounds
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
WO2009006404A2 (en) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009085256A1 (en) * 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
CA2722811C (en) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
CN102666526A (zh) 2009-10-21 2012-09-12 贝林格尔.英格海姆国际有限公司 作为ccr1受体拮抗剂的吲唑和吡唑并吡啶化合物
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしての複素環化合物
US20110137042A1 (en) 2009-12-08 2011-06-09 Boehringer Ingelheim International Gmbh Process for Synthesis of Intermediates Useful for Making Substituted Indazole and Azaindazole Compounds
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists

Also Published As

Publication number Publication date
MA32655B1 (fr) 2011-09-01
US8338610B2 (en) 2012-12-25
MX2011002951A (es) 2011-04-26
US20120136158A1 (en) 2012-05-31
CA2737472A1 (en) 2010-04-01
CN102227425A (zh) 2011-10-26
IL210857A0 (en) 2011-04-28
UA103634C2 (en) 2013-11-11
TW201018683A (en) 2010-05-16
UY32140A (es) 2010-04-30
EP2346868A1 (en) 2011-07-27
JP2012503664A (ja) 2012-02-09
AR073689A1 (es) 2010-11-24
NZ591115A (en) 2012-10-26
US7879873B2 (en) 2011-02-01
AU2009296839A1 (en) 2010-04-01
AP2011005685A0 (en) 2011-04-30
US8163918B2 (en) 2012-04-24
US8063065B2 (en) 2011-11-22
EP2346868B1 (en) 2016-01-27
ZA201100625B (en) 2011-09-28
CO6351735A2 (es) 2011-12-20
JP5507567B2 (ja) 2014-05-28
ECSP11010932A (es) 2011-04-29
AP2739A (en) 2013-09-30
PE20110854A1 (es) 2011-12-23
WO2010036632A1 (en) 2010-04-01
US20110086846A1 (en) 2011-04-14
KR20110060904A (ko) 2011-06-08
US20120035370A1 (en) 2012-02-09
CL2011000668A1 (es) 2011-10-28
BRPI0919844A2 (pt) 2019-09-24
US20100093724A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
NO20073182L (no) Indazol-karboksamidforbindelser
DOP2009000263A (es) Antagonistas piridil piperdina del receptor de orexina
EA201000006A1 (ru) Способы и композиции для лечения аллергических заболеваний
EA201400624A1 (ru) Замещенные 4-фенилпиридины для лечения болезней, связанных с рецептором nk-1
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201070238A1 (ru) Соединения пиримидина
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA200970765A1 (ru) 2-аминопиримидиновые модуляторы рецептора hгистамина
EA201001522A1 (ru) Новые p2x7r антагонисты и их применение
EA200970113A1 (ru) Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen
EA201100088A1 (ru) Пиперидинильное производное как модулятор активности хемокинового рецептора